Mr van den Dool has more than 25 years’ experience in the life science industry and with his expertise in sales and operations strategy in EMEA. He currently serves as Head of Research and Applied Solutions, Western Europe Commercial, for the Life Science business of Merck.
Prior to this, he was Managing Director EMEA at Sigma-Aldrich, where he held various sales and operational leadership roles, both in the US and Europe since joining the company in 2009.
Mr van den Dool has also worked in a range of positions at Amersham Pharmacia, Molecular Dynamics, Applied Biosystems and Spectra Physics. He holds an Engineering degree in Applied Physics.
Dan Calvo, CEO of Gyros Protein Technologies, said: “We welcome Gerrit to our Board of Directors, and look forward to benefitting from his wealth of knowledge and guidance as Gyros Protein Technologies continues to grow and expand our footprint in new markets.”
Gerrit van den Dool said: “I am delighted to join Gyros Protein Technologies’ Board and look forward to being a part of the next stage of development for this exciting company.”
Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ knowledge in developing and manufacturing instruments for peptide synthesis.
The Company provides customers with a range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing.